GLP-1 weight-loss drugs found to reduce life-threatening "no-reflow" complications following a heart attack

A University of Bristol study finds GLP-1 drugs relax pericytes to prevent "no-reflow" and tissue damage after a heart attack.

By: AXL Media

Published: Mar 3, 2026, 5:19 AM EST

Source: The information in this article was sourced from University of Bristol

Addressing the "no-reflow" complication

A significant challenge in cardiovascular medicine is that nearly 50 percent of heart attack patients experience continued lack of blood flow to heart tissue after the primary blocked artery has been cleared. This phenomenon, known as "no-reflow," occurs when microscopic blood vessels within the heart muscle remain constricted. According to researchers at Bristol Medical School, this complication drastically increases the risk of heart failure or death within a year of the initial attack. New findings suggest that GLP-1 drugs, commonly used for weight loss and diabetes, may provide a solution to this persistent clinical problem.

Mechanism of heart tissue protection

The study, published in Nature Communications, utilized animal models to observe how GLP-1 drugs interact with specific heart cells called pericytes. Pericytes are small contractile cells that wrap around coronary capillaries and regulate their diameter. During a heart attack (ischemia), these cells constrict, cutting off oxygen-rich blood. The research team discovered that GLP-1 drugs activate potassium channels within these pericytes, causing them to relax. This relaxation allows the tiny capillaries to dilate, restoring critical blood flow and preventing further damage to the heart muscle.

Broad applications for existing medications

GLP-1 (glucagon-like peptide-1) mimicking drugs, such as Ozempic and Wegovy, have already demonstrated the ability to lower the risk of serious cardiovascular problems. However, this study is the first to identify pericytes as the primary effector in this protective process. Professor David Attwell of UCL noted that because these drugs are already in widespread clinical use for obesity, type 2 diabetes, and kidney disease, they could be rapidly repurposed as a life-saving treatment specifically for heart attack recovery.